

# **UNIQUE “ MGSMM ” OF ALL CANCERS ONE CLASSIFICATION © ®** **EFRUZHU NORTH CYPRUS (TURKISH CYPRIOT)** **CLINICAL MEDICAL ONCOLOGY STAGING SYSTEM**

**MOLECULAR GENETIC      HISTOPATHOLOGY      STAGE      METASTASES**

<b>M1</b>	<b>G1</b>	<b>S1</b>	<b>M1</b>
<b>M2</b>	<b>G2</b>	<b>S2</b>	
<b>M3</b>	<b>G3</b>	<b>S3</b>	<b>M2</b>
<b>M4</b>	<b>G4</b>	<b>S4</b>	

**M1:% 0 – 25      TOTAL WILD DNA MUTATIONS PROPORTION**  
**M2:% 26 – 50      TOTAL WILD DNA MUTATIONS PROPORTION**  
**M3:% 51 – 75      TOTAL WILD DNA MUTATIONS PROPORTION**  
**M4:% 76 – 100      TOTAL WILD DNA MUTATIONS PROPORTION**

**G1:GRADE 1 WELL      DIFFERENTIATED**  
**G2:GRADE 2 MODERATELY DIFFERENTIATED**  
**G3:GRADE 3 POORLY DIFFERENTIATED**  
**G4:GRADE 4 UNDIFFERENTIATED**

**S1:CLINICAL STAGE DISEASE/PATIENTS**  
**S2:CLINICAL STAGE DISEASE/PATIENTS**  
**S3:CLINICAL STAGE DISEASE/PATIENTS**  
**S4:CLINICAL STAGE DISEASE/PATIENTS**

**M1:LOCOREGIONAL-NEARBY (LOCAL REGIONAL) LYMPH NODES METASTASES**  
**M2:DISTANT METASTASES**

**STAGING OF CLINICAL MEDICAL ONCOLOGY FIGURES:**

**1)MOLECULAR FIGURE 2)PATHOLOGIC FIGURE 3)CLINICAL FIGURE 4)CLINICAL TRIAL FIGURE**

